Systematic Review on the Efficacy and Safety of Erenumab for the Prevention of Migraine
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 손병우 | - |
dc.contributor.author | 채현우 | - |
dc.contributor.author | 지은희 | - |
dc.contributor.author | 유봉규 | - |
dc.date.available | 2020-02-27T06:41:16Z | - |
dc.date.created | 2020-02-12 | - |
dc.date.issued | 2019-06 | - |
dc.identifier.issn | 1226-6051 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/2445 | - |
dc.description.abstract | Objective: This study aimed to provide efficacy and safety information on the use of erenumab for prevention of episodic and chronic migraines. Methods: The keywords “Erenumab and migraine” were used to search the PubMed database to then compile efficacy and safety data for erenumab. Data from relevant Phase 2 and Phase 3 clinical trials were analyzed, using RevMan for statistical analysis. Results: Three clinical trials (one Phase 2 and two Phase 3 studies) were retrieved. All three trials used the same primary endpoint (change from baseline in monthly migraine days (CBMD)) to evaluate efficacy and safety of erenumab use for prevention of episodic and chronic migraines. Subcutaneous doses of erenumab (70 or 140 mg) were administered monthly in each trial, for 3 months (Studies 2, and 3) or 6 months (Study 1). The mean differences in CBMD in the 70 mg and 140 mg erenumab arms were -1.36 and -1.98, respectively, compared to that in the placebo arm. Some adverse events, such as nasopharyngitis and upper respiratory tract infection, were reported, but no differences in safety between erenumab and placebo were found to be significant. Conclusions: Erenumab showed superior efficacy in prevention of migraines compared to placebo. However, additional information regarding the long-term safety of erenumab should be collected. Therefore, post-marketing surveillance for adverse events is needed. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | 한국임상약학회 | - |
dc.relation.isPartOf | 한국임상약학회지 | - |
dc.title | Systematic Review on the Efficacy and Safety of Erenumab for the Prevention of Migraine | - |
dc.title.alternative | 편두통 예방을 위한 erenumab의 유효성 및 안전성에 관한 체계적 고찰 | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 2 | - |
dc.identifier.doi | 10.24304/kjcp.2019.29.2.71 | - |
dc.identifier.bibliographicCitation | 한국임상약학회지, v.29, no.2, pp.71 - 78 | - |
dc.identifier.kciid | ART002482714 | - |
dc.description.isOpenAccess | N | - |
dc.citation.endPage | 78 | - |
dc.citation.startPage | 71 | - |
dc.citation.title | 한국임상약학회지 | - |
dc.citation.volume | 29 | - |
dc.citation.number | 2 | - |
dc.contributor.affiliatedAuthor | 손병우 | - |
dc.contributor.affiliatedAuthor | 채현우 | - |
dc.contributor.affiliatedAuthor | 지은희 | - |
dc.contributor.affiliatedAuthor | 유봉규 | - |
dc.subject.keywordAuthor | Erenumab | - |
dc.subject.keywordAuthor | CGRP receptor antagonist | - |
dc.subject.keywordAuthor | migraine | - |
dc.subject.keywordAuthor | clinical trials | - |
dc.subject.keywordAuthor | adverse events | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.